They sign the first agreement to produce a generic drug for cancer

For the first time the generic version of a drug against a type of cancer could be produced in developing countries and sold to other countries with a similar economy with the authorization of the pharmaceutical company that developed it and has been producing it for almost twenty years.

The Medicine Patent Pool (MPP), a public health organization supported by the UN, announced today that it has signed an agreement with the Swiss company Novartis that will facilitate access to the drug nilotinib, an oral medication used as second-generation treatment of chronic myeloid leukemia.

The novelty is that 44 developing countries will be able to acquire generic nilotinib at a price that is probably negligible compared to the original product. The MPP hopes that at least three generic versions will be produced, which would create optimal conditions for competition in the market.

In cases of similar agreements in relation to drugs for other diseases, generics ended up costing up to 90% less.

Among the beneficiaries is a group of countries where the patent for this product will extend beyond July 2023, when the pharmaceutical company’s intellectual property rights will expire in several low- and middle-income countries.

Read Also:  Police Officer's Service Weapon Stolen by Two Criminals on Duty: Investigation Underway

Recent Articles

Related News

Leave A Reply

Please enter your comment!
Please enter your name here